Mavenclad (Cladribine Tablets)

New treatment option for relapsing remitting MS

The National Centre for Pharmacoeconomics in Ireland (NCPE) announces positive recommendation for reimbursement for MAVENCLAD (Cladribine tablets). 

MS Ireland believes people with MS should have access to all and any appropriate and licensed treatments that would improve or assist in the management of their condition. The MS community is very much looking forward to having access to this treatment option.

Read MS Ireland’s briefing document on the process of licensing and reimbursement of new medications.